MeMed announced the publication of three new peer-reviewed studies, demonstrating the impact of MeMed BV, its flagship diagnostic for differentiating between bacterial and viral infections.
Study 1: Published in BMC Medicine (Kalmovich et al.), this large-scale, real-world study evaluated 3,920 patients across 10 urgent care centers, involving 144 physicians using MeMed BV in routine practice. Key findings:
- 63% reduction in unnecessary antibiotic prescriptions.
- 70% of previously potentially missed bacterial infections correctly identified and treated, leading to significantly lower hospitalization rates (7.8% vs. 30.3%).
- Helped in preventing emergency department (ED) referrals in 20% of patients.
Study 2: Published in Clinical Infectious Diseases (Allen C et al.), this study examined 1,016 patients across 17 centers in the U.S. and EMEA, with a focus on.
Study 3: Published in JAC-AMR (Gregg E et al.), this study assessed MeMed BV’s economic impact within the UK’s National Health Service (NHS), revealing:
- Significant cost savings in testing for community-acquired pneumonia across both adult and pediatric populations, reinforcing its value in optimizing healthcare expenditures.
